Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KU-0060648 is a potent, dual small molecule inhibitor of **DNA-dependent protein kinase (DNA-PK)** and **phosphoinositide 3-kinases (PI3Ks)**, showing highest potency against the PI3Kδ isoform and substantial activity against DNA-PK and other class I PI3K isoforms (PI3Kα, PI3Kβ)[1][3][5][8]. It selectively blocks the repair of DNA double-strand breaks by inhibiting DNA-PK, interfering with non-homologous end joining (NHEJ) repair, and suppresses the PI3K/AKT pathway involved in cellular growth and survival[1][3][5][8]. The compound was designed as an anti-cancer agent; it inhibits proliferation in multiple cancer cell lines (notably MCF7 breast cancer and LoVo colon cancer), both as a single agent and as a chemosensitizer in combination with topoisomerase II poisons such as etoposide and doxorubicin[1][3][5]. It demonstrates cell-line- and context-dependent anti-tumor activity and enhances the efficacy of DNA-damaging chemotherapies[1]. KU-0060648 has also been used to improve CRISPR/Cas9-mediated homology-directed repair by inhibiting NHEJ and favoring homologous recombination[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KU-0060648.